👤 Omar Faruk Talukder

Eichhornia crassipes (Mart.) Solms, also known as Pontederia crassipes Mart, has traditionally been used for its sedative, antipsychotic, and memory-enhancing properties. However, its effects against Alzheimer's disease (AD) remain unexplored. Therefore, this study aimed to investigate the in vitro anti-AD properties of methanol (MEECF), ethanol (EEECF), and ethyl acetate (EAEECF) extracts of E. crassipes flowers and to identify potential multi-modal anti-AD phytocompounds using computational drug discovery targeting acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1). Initially, 204 phytocompounds were metabolically annotated through GC-MS analysis of the extracts, and their functional groups and chemical nature were identified using PPS and FT-IR analysis, respectively. Molecular docking identified two hit phytocompounds (CID 4970, fumarine, and CID 106962, cyclopentanemethanamine, 5-amino-2,2,4-trimethyl-) in MEECF and EEECF, which exhibited higher binding affinities toward all targets compared to the control drug donepezil (-5.721 kcal/mol). Further molecular analysis revealed favorable pharmacokinetics, drug-likeness, and no toxicity for these two phytocompounds. Molecular dynamics simulation confirmed their binding stability to the active sites of AChE, BChE, and BACE-1, exhibiting multi-modal inhibitory activity. MEECF, EEECF, and EAEECF showed concentration-dependent antioxidant and AChE and BChE inhibition, supporting the in silico results regarding oxidative stress and cholinergic pathways. These findings suggest the anti-AD potential of E. crassipes flowers, with fumarine and cyclopentanemethanamine, 5-amino-2, 2, 4-trimethyl- identified as multi-modal inhibitors of AChE, BChE, and BACE-1. However, further in vivo research is required to comprehensively evaluate their efficacy in combating AD. Show less

Alzheimer's disease (AD) represents a significant global health challenge due to its complex pathophysiology and limited therapeutic options. Traditional drug discovery methods have had limited success, highlighting the need for innovative strategies. This systematic review evaluates the role of molecular docking, virtual screening, and molecular dynamics simulations in the early stages of AD drug discovery. This study reviewed 100 studies published between 2000 and 2024, focusing on computational approaches to identify and optimize drug candidates targeting key AD-related proteins, including acetylcholinesterase (AChE), β-secretase (BACE1), and tau. Both natural and synthetic compounds were examined, emphasizing studies integrating in silico methods with in vitro and in vivo validations. AChE was the most frequently targeted protein (23 studies), followed by BACE1 and multi-target approaches. The compounds investigated varied, with 35 studies focusing on natural products (e.g., quercetin, huperzine A) and 54 on synthetic analogs (e.g., tacrine derivatives). Integrating computational and experimental methods enhanced the validation process, providing comprehensive insights into the pharmacodynamics and pharmacokinetics of potential therapeutics. Computational approaches significantly expedite the identification and optimization of AD drug candidates by enabling the rapid screening of extensive compound libraries. These methods, when combined with experimental validations, offer deeper molecular-level insights into drug interactions and mechanisms. However, challenges such as predictive accuracy and data quality remain, necessitating further advancements in computational models and data integration to improve the predictability and effectiveness of AD therapeutics. Show less

Dyggve-Melchior-Clausen (DMC) syndrome was described in 1962 as an autosomal recessive type of spondyloepimetaphyseal dysplasia associated with mental retardation. Dymeclin (DYM) gene on chromosome 18q12.1 that encodes for DYM protein which is expressed in cartilage, bone, and brain is mutated in DMC. A 6 year -old male child presented with bilateral gradually progressive genu varum deformity of 4 years' duration. There was no significant past medical and family history. A plain radiograph of his knee, pelvis, and spine shows some classical signs of skeletal dysplasia. A plain radiograph of the pelvis with both hips shows a classical semilunar, irregular lacy appearance around the iliac crest which is a pathognomonic radiological sign of this syndrome. The radiographic lacy appearance of iliac crests and generalized platyspondyly with double-humped end plates are pathognomonic of DMC. Show less